CRMD insider Form 144 files for 50,000-share sale on NASDAQ

Rhea-AI Filing Summary

CorMedix Inc. (CRMD) submitted a Form 144 notice reporting a proposed sale of 50,000 common shares through Merrill Lynch on NASDAQ with an approximate aggregate market value of $673,000. The filing lists total shares outstanding as 74,648,992 and shows the securities were acquired under Stock Plan Activity on 09/09/2025, with the intended sale date also 09/09/2025. The filer indicates there were no securities sold in the past three months by the reporting person. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Positive

• Full disclosure of sale mechanics: acquisition date, broker, number of shares, aggregate value, and exchange are provided
• No sales in prior three months by the reporting person, reducing immediate concentration of insider selling

Negative

• Lack of identifying details about the specific selling person and their relationship to the issuer beyond the generic field
• Same-day acquisition and sale date (09/09/2025) may raise questions for investors seeking context, but no additional explanation is provided

Insights

Securities Analyst

TL;DR: Officer/insider plans to sell a modest stake (50k shares) acquired via stock plan, representing a small fraction of outstanding shares.

The Form 144 indicates an insider or affiliate intends to liquidate equity obtained through a stock plan on the same date as acquisition, which may simply reflect planned disposition under Rule 144 procedures. The size—50,000 shares versus 74.6 million outstanding—equals roughly 0.067% of outstanding stock, indicating limited potential market impact. The filing states no prior sales in the preceding three months and includes the required certification regarding material nonpublic information.

Corporate Governance Specialist

TL;DR: Compliance filing shows standard insider sale mechanics; key disclosure obligations appear met.

The document documents a Rule 144 notice tied to stock-plan activity and names a broker (Merrill Lynch). It provides required details: acquisition date, nature of acquisition, sale date, and representation about material information. From a governance perspective, the filing fulfills procedural transparency for insider dispositions but does not provide context on insider role or rationale beyond the mechanics.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006	50000	673000.00	74648992	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2025	Stock Plan Activity	Issuer			50000	09/09/2025	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by CorMedix (CRMD) report?

The Form 144 reports a proposed sale of 50,000 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $673,000.

When were the shares in the Form 144 acquired?

The filing states the shares were acquired on 09/09/2025 through Stock Plan Activity and the date of payment is listed as 09/09/2025.

How many CorMedix shares are outstanding according to the filing?

The filing lists 74,648,992 shares outstanding.

Did the filing report any sales by the person in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale in the Form 144?

The broker listed is Merrill Lynch, 1800 K St NW, Suite 800, Washington DC 20006.